Feasibility study of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients

Feasibility study of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients - Feasibility study of sentinel lymph node biopsy following neoadjuvant chemotherapy in breast cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006534

Enrollment

240

Registered

2011-10-30

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Sentinel lymph node biopsy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically proven breast cancer. 2.TNM classification is T1-T3 and N1,M0. 3.Axillary lymph nodes metastasis was detected by fine needle aspiration biopsy before NAC. 4.NAC was performed. 5.Axillary lymph nodes metastasis was comfirmed to change negative by biopsy orUS after NAC. 6.Axillary lymph node dissection will be performed after SLNB. 7.Patients aged 20 and over years old. 8.ECOG performance status (PS) of 0or1. 9.Sufficient organ functions. 10.Witten informed consent.

Exclusion criteria

Exclusion criteria: 1.History of undergo sentinel lymph node biopsy 2.Ipsilateral breast tumor recurrence 3.Inflammatory breast cancer 4.Bilateral breast cancer 5.Women during pregnancy or breast-feeding. 6.Disqualified by doctors

Design outcomes

Primary

Measure	Time frame
False-negative rate	—

Secondary

Measure	Time frame
Idenfication rate	—

Countries

Japan

Contacts

Public ContactChie Watanabe

Showa University hospital Breast Center

chie.watanabe0320@gmail.com03-3784-8727

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026